Is my current management appropriate for a 46‑year‑old male (84 kg) with hypertension, type 2 diabetes, chronic kidney disease stage 3b (eGFR ≈ 35 mL/min), dyslipidaemia, and a prior below‑knee amputation, given his uncontrolled blood pressure (~160/100 mmHg) and current medications (losartan, linagliptin, rosuvastatin, keto‑analogue)?

Management Review for 46-Year-Old Male with Uncontrolled Hypertension, T2DM, and CKD Stage 3b

Your management plan requires several critical modifications, particularly the addition of an SGLT2 inhibitor and consideration of blood pressure intensification beyond single-agent ARB therapy.

Critical Gaps in Current Management

Missing SGLT2 Inhibitor Therapy

You must add an SGLT2 inhibitor immediately – this is the most significant omission in your current plan. 1, 2

• With eGFR 35 mL/min (CKD G3b) and T2DM, SGLT2 inhibitors are strongly recommended (Grade 1A) for patients with eGFR ≥20 mL/min/1.73 m² 1, 2
• These agents provide kidney protection, cardiovascular benefits, and reduce progression to kidney failure independent of glucose-lowering effects 1, 2
• The patient's eGFR of 35 mL/min is well above the initiation threshold of 20 mL/min 1
• Once started, SGLT2 inhibitors should be continued even if eGFR falls below 20 mL/min unless dialysis is initiated 1, 3

Blood Pressure Management Issues

Your switch from losartan 50 mg to telmisartan 80 mg is appropriate but likely insufficient as monotherapy. 4

• Target BP for this patient with CKD and diabetes should be 120-130 mmHg systolic 4
• Current BP of 160/100 mmHg (confirmed 150/100 mmHg) requires multi-drug therapy 4, 5
• The 2024 ESC guidelines recommend systolic BP target of 120-129 mmHg in adults with moderate-to-severe CKD (eGFR >30 mL/min/1.73 m²) if tolerated 4
• You should add a calcium channel blocker (CCB) or thiazide-like diuretic as second-line therapy immediately rather than waiting to assess telmisartan response alone 4, 5

Albuminuria Assessment Missing

You must check urine albumin-to-creatinine ratio (ACR) urgently – this is essential for risk stratification and treatment decisions. 1, 2

• Albuminuria status determines whether to add nonsteroidal mineralocorticoid receptor antagonist (finerenone) 1, 6
• If ACR ≥30 mg/g despite maximum tolerated RAS inhibition, finerenone should be considered (Grade 2A recommendation) 1, 6
• Albuminuria is one of the strongest predictors of CKD progression and cardiovascular events 1, 7

Appropriate Elements of Your Plan

Lipid Management

Rosuvastatin 20 mg is appropriate for this high-risk patient with LDL 124.61 mg/dL. 8, 9

• Patients with CKD and diabetes require intensive lipid lowering to reduce cardiovascular disease burden 8
• Target LDL should be <70 mg/dL given established cardiovascular risk factors 8

Diabetes Management

Continuing linagliptin 5 mg is acceptable but not optimal given missing SGLT2 inhibitor. 10

• Linagliptin is safe in CKD and requires no dose adjustment 10
• However, it should be considered adjunctive therapy after SGLT2 inhibitor initiation 1, 2
• Current FBS 86.49 mg/dL suggests reasonable glycemic control, but HbA1c is needed for full assessment 11

Ketoanalogue Therapy

Ketoanalogue supplementation is reasonable for CKD G3b but evidence is limited. 1

• May help reduce uremic symptoms and slow progression in advanced CKD 1
• Not a substitute for primary kidney-protective therapies (RAS inhibition, SGLT2 inhibitors) 1

Hyperkalemia Monitoring

Your potassium of 5.03 mmol/L requires close monitoring but is not a contraindication to RAS inhibition. 1, 2, 12

• Continue telmisartan unless potassium rises >5.5 mmol/L or creatinine increases >30% within 4 weeks 1, 2
• Hyperkalemia can often be managed with dietary modification, diuretics, or potassium binders rather than stopping RAS inhibition 1, 2
• Recheck potassium and creatinine within 2-4 weeks of telmisartan initiation 2, 11
• Do not add finerenone until potassium is consistently <4.8 mmol/L 6, 11

Recommended Management Algorithm

Immediate Actions (Within 1-2 Weeks):

1. Add SGLT2 inhibitor (empagliflozin 10 mg, dapagliflozin 10 mg, or canagliflozin 100 mg daily) 1, 2
2. Add second antihypertensive agent: amlodipine 5-10 mg daily or chlorthalidone 12.5-25 mg daily 4, 5
3. Order urine albumin-to-creatinine ratio 1, 2
4. Obtain HbA1c (you appropriately ordered this) 11

Follow-up at 2-4 Weeks:

1. Recheck BP, creatinine, potassium 2, 11
2. Assess tolerability of new medications 1
3. Titrate antihypertensives if BP remains >130/80 mmHg 4

Follow-up at 3 Months:

1. Review albuminuria results 1, 2
2. If ACR ≥30 mg/g and potassium <4.8 mmol/L: consider adding finerenone 10-20 mg daily 6, 11
3. Reassess BP control: target 120-130 mmHg systolic 4
4. Review HbA1c: adjust diabetes medications if needed 11

Critical Pitfalls to Avoid

• Do not delay SGLT2 inhibitor initiation – this is the single most important missing therapy 1, 2
• Do not rely on single-agent ARB therapy for BP 160/100 mmHg – immediate combination therapy is needed 4, 5
• Do not stop telmisartan for potassium 5.03 mmol/L – manage hyperkalemia with other strategies first 1, 2
• Do not add finerenone without checking albuminuria and ensuring potassium <4.8 mmol/L 6, 11
• Do not withhold SGLT2 inhibitor if eGFR drops acutely after initiation – this is expected and reversible 1, 2